cadonilimab   Click here for help

GtoPdb Ligand ID: 12966

Synonyms: AK-104 | AK104
Approved drug Immunopharmacology Ligand
cadonilimab is an approved drug (China NMPA (2022))
Compound class: Antibody
Comment: Cadonilimab (AK104) is a humanized, bispecific monoclonal antibody that simultaneously targets the immune checkpoint proteins PD-1 and CTLA-4. It was designed as a cancer immunotherapy (immuno-oncology) agent.
Click here for help
Classification Click here for help
Compound class Antibody
Approved drug? Yes (China NMPA (2022))
International Nonproprietary Names Click here for help
INN number INN
11581 cadonilimab
Synonyms Click here for help
AK-104 | AK104
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 1124
Other databases
GtoPdb PubChem SID 485206087
Search PubMed clinical trials cadonilimab
Search PubMed titles cadonilimab
Search PubMed titles/abstracts cadonilimab